Inventor · disambiguated record
Joanna Röder
Also filed as: RODER JOANNA · ROEDER JOANNA · RÖDER JOANNA
24 granted patents·7 pending applications·154 citations·filing 2012–2024
95Inventor score
Top patents by PatentIndex Score
31 records- 0196US8718996B2Method for predicting whether a cancer patient will not benefit from platinum-based chemotherapy agentsBIODESIX INC·Filed 2013·Granted May 6, 2014·19 cites·10 claims
- 0295US10489550B2Predictive test for aggressiveness or indolence of prostate cancer from mass spectrometry of blood-based sampleBIODESIX INC·Filed 2017·Granted Nov 26, 2019·13 cites·7 claims
- 0393US10007766B2Predictive test for melanoma patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methodsBIODESIX INC·Filed 2016·Granted Jun 26, 2018·9 cites·8 claims
- 0493US9779204B2Predictive test for aggressiveness or indolence of prostate cancer from mass spectrometry of blood-based sampleBIODESIX INC·Filed 2015·Granted Oct 3, 2017·7 cites·6 claims
- 0593US9563744B1Method of predicting development and severity of graft-versus-host diseaseBIODESIX INC·Filed 2015·Granted Feb 7, 2017·9 cites·11 claims
- 0693US9477906B2Classification generation method using combination of mini-classifiers with regularization and uses thereofBIODESIX INC·Filed 2014·Granted Oct 25, 2016·21 cites·39 claims
- 0792US10217620B2Early detection of hepatocellular carcinoma in high risk populations using MALDI-TOF mass spectrometryBIODESIX INC·Filed 2018·Granted Feb 26, 2019·6 cites·10 claims
- 0891US11894147B2Method for predicting risk of unfavorable outcomes, e.g., in COVID-19 hospitalization, from clinical characteristics and basic laboratory findingsBIODESIX INC·Filed 2022·Granted Feb 6, 2024·2 cites·7 claims
- 0991US10037874B2Early detection of hepatocellular carcinoma in high risk populations using MALDI-TOF mass spectrometryBIODESIX INC·Filed 2015·Granted Jul 31, 2018·6 cites·9 claims
- 1090US11594403B1Predictive test for prognosis of myelodysplastic syndrome patients using mass spectrometry of blood-based sampleBIODESIX INC·Filed 2018·Granted Feb 28, 2023·4 cites·11 claims
- 1190US11476003B2Method for predicting risk of unfavorable outcomes, e.g., in COVID-19 hospitalization, from clinical characteristics and basic laboratory findingsBIODESIX INC·Filed 2021·Granted Oct 18, 2022·3 cites·10 claims
- 1290US8467988B1Method and system for validation of mass spectrometer machine performanceROEDER JOANNA·Filed 2013·Granted Jun 18, 2013·18 cites·20 claims
- 1389US9211314B2Treatment selection for lung cancer patients using mass spectrum of blood-based sampleBIODESIX INC·Filed 2014·Granted Dec 15, 2015·6 cites·30 claims
- 1489US8914238B2Method for predicting breast cancer patient response to endocrine therapyRÖDER JOANNA·Filed 2012·Granted Dec 16, 2014·12 cites·7 claims
- 1587US10713590B2Bagged filtering method for selection and deselection of features for classificationBIODESIX INC·Filed 2016·Granted Jul 14, 2020·5 cites·24 claims
- 1687US9254120B2Method for predicting breast cancer patient response to combination therapyBIODESIX INC·Filed 2013·Granted Feb 9, 2016·5 cites·8 claims
- 1785US10950348B2Predictive test for patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methodsBIODESIX INC·Filed 2018·Granted Mar 16, 2021·2 cites·11 claims
- 1882US2025336497A1Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereofIOVANCE BIOTHERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1979US11150238B2Method for identification of cancer patients with durable benefit from immunotherapy in overall poor prognosis subgroupsBIODESIX INC·Filed 2018·Granted Oct 19, 2021·1 cites·8 claims
- 2077US12094587B2Apparatus and method for identification of primary immune resistance in cancer patientsBIODESIX INC·Filed 2019·Granted Sep 17, 2024·1 cites·19 claims
- 2175US11710539B2Predictive test for melanoma patient benefit from interleukin-2 (IL2) therapyBIODESIX INC·Filed 2017·Granted Jul 25, 2023·1 cites·4 claims
- 2275US9653272B2Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapiesBIODESIX INC·Filed 2013·Granted May 16, 2017·2 cites·72 claims
- 2374US11621057B2Classifier generation methods and predictive test for ovarian cancer patient prognosis under platinum chemotherapyBIODESIX INC·Filed 2017·Granted Apr 4, 2023·1 cites·11 claims
- 2474US10593529B2Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapiesBIODESIX INC·Filed 2017·Granted Mar 17, 2020·1 cites·15 claims
- 2574US2023197426A1Predictive test for prognosis of myelodysplastic syndrome patients using mass spectrometry of blood-based sampleBIODESIX INC·Filed 2023·Application pending·0 cites
- 2670US12230398B2Predictive test for patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methodsBIODESIX INC·Filed 2020·Granted Feb 18, 2025·0 cites·7 claims
- 2769US2022026416A1Method for identification of cancer patients with durable benefit from immunotehrapy in overall poor prognosis subgroupsBIODESIX INC·Filed 2021·Application pending·0 cites
- 2864US2021369775A1Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereofIOVANCE BIOTHERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2959US2014200825A1Method for predicting whether a cancer patient will not benefit from platinum-based chemotherapy agentsBIODESIX INC·Filed 2014·Application pending·0 cites
- 3055US2016019342A1Treatment selection for lung cancer patients using mass spectrum of blood-based sampleBIODESIX INC·Filed 2015·Application pending·0 cites
- 3147US2022341939A1Predictive test for identification of early stage nsclc stage patients at high risk of recurrence after surgeryBIODESIX INC·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Joanna Röder files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →